Investigators delivered updated results from the phase 3 PHILA trial evaluating the pyrotinib or placebo plus trastuzumab and docetaxel in patients with untreated HER2+metastatic breast cancer.

Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL Additional ASH data from investigational BTK ...

Clinically meaningful activity was observed in 57 patients at 400 mg BID fed, including 11.1-month median PFS and mutation-subtype–agnostic benefit across kinase versus nonkinase PIK3CA variants.

Investigators sought to determine whether adding gedatolisib to fulvestrant, with or without palbociclib, improved clinical outcomes in patients with HR-positive/HER2-negative/PIK3CA wild-type ...

In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable ...

Adding lenvatinib to pembrolizumab improved PFS (6.2 vs 2.8 months; HR 0.64) and ORR (46.1% vs 25.4%) versus pembrolizumab alone in PD-L1 CPS ≥1 disease. Overall survival was not improved at 21.3 ...

CHICAGO — First-line NALIRIFOX significantly extended in OS and PFS vs. gemcitabine and nab-paclitaxel among patients with treatment-naive metastatic pancreatic ductal adenocarcinoma, according to a ...

Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...

Niraparib monotherapy in HRd EOC patients showed longer rwPFS and rwTTNT, particularly in BRCA-mutated tumors, compared to the overall population. The study used Flatiron Health data, focusing on US ...

The MarketWatch News Department was not involved in the creation of this content. Multiple long-term follow-up studies confirm BRUKINSA's superior efficacy and favorable tolerability versus ibrutinib ...